The importance of meropenem resistance, rather than imipenem resistance, in defining carbapenem-resistant Enterobacterales for public health surveillance: an analysis of national population-based surveillance.
Carbapenem-resistant Enterobacterales
Carbapenemase-producing Enterobacterales
IMP-type metallo-β-lactamase
Imipenem
Meropenem
Multidrug resistance
Surveillance definition
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
15 Feb 2024
15 Feb 2024
Historique:
received:
20
10
2023
accepted:
06
02
2024
medline:
16
2
2024
pubmed:
16
2
2024
entrez:
15
2
2024
Statut:
epublish
Résumé
In Japan, carbapenem-resistant Enterobacterales (CRE) infections were incorporated into the National Epidemiological Surveillance of Infectious Diseases (NESID) in 2014, necessitating mandatory reporting of all CRE infections cases. Subsequently, pathogen surveillance was initiated in 2017, which involved the collection and analysis of CRE isolates from reported cases to assess carbapenemase gene possession. In this surveillance, CRE is defined as (i) minimum inhibitory concentration (MIC) of meropenem ≥2 mg/L (MEPM criteria) or (ii) MIC of imipenem ≥2 mg/L and MIC of cefmetazole ≥64 mg/L (IPM criteria). This study examined whether the current definition of CRE surveillance captures cases with a clinical and public health burden. CRE isolates from reported cases were collected from the public health laboratories of local governments, which are responsible for pathogen surveillance. Antimicrobial susceptibility tests were conducted on these isolates to assess compliance with the NESID CRE definition. The NESID data between April 2017 and March 2018 were obtained and analyzed using antimicrobial susceptibility test results. In total, 1681 CRE cases were identified during the study period, and pathogen surveillance data were available for 740 (44.0%) cases. Klebsiella aerogenes and Enterobacter cloacae complex were the dominant species, followed by Klebsiella pneumoniae and Escherichia coli. The rate of carbapenemase gene positivity was 26.5% (196/740), and 93.4% (183/196) of these isolates were of the IMP type. Meanwhile, 315 isolates were subjected to antimicrobial susceptibility testing. Among them, 169 (53.7%) fulfilled only the IPM criteria (IPM criteria-only group) which were susceptible to meropenem, while 146 (46.3%) fulfilled the MEPM criteria (MEPM criteria group). The IPM criteria-only group and MEPM criteria group significantly differed in terms of carbapenemase gene positivity (0% vs. 67.8%), multidrug resistance rates (1.2% vs. 65.8%), and mortality rates (1.8% vs 6.9%). The identification of CRE cases based solely on imipenem resistance has had a limited impact on clinical management. Emphasizing resistance to meropenem is crucial in defining CRE, which pose both clinical and public health burden. This emphasis will enable the efficient allocation of limited health and public health resources and preservation of newly developed antimicrobials.
Sections du résumé
BACKGROUND
BACKGROUND
In Japan, carbapenem-resistant Enterobacterales (CRE) infections were incorporated into the National Epidemiological Surveillance of Infectious Diseases (NESID) in 2014, necessitating mandatory reporting of all CRE infections cases. Subsequently, pathogen surveillance was initiated in 2017, which involved the collection and analysis of CRE isolates from reported cases to assess carbapenemase gene possession. In this surveillance, CRE is defined as (i) minimum inhibitory concentration (MIC) of meropenem ≥2 mg/L (MEPM criteria) or (ii) MIC of imipenem ≥2 mg/L and MIC of cefmetazole ≥64 mg/L (IPM criteria). This study examined whether the current definition of CRE surveillance captures cases with a clinical and public health burden.
METHODS
METHODS
CRE isolates from reported cases were collected from the public health laboratories of local governments, which are responsible for pathogen surveillance. Antimicrobial susceptibility tests were conducted on these isolates to assess compliance with the NESID CRE definition. The NESID data between April 2017 and March 2018 were obtained and analyzed using antimicrobial susceptibility test results.
RESULTS
RESULTS
In total, 1681 CRE cases were identified during the study period, and pathogen surveillance data were available for 740 (44.0%) cases. Klebsiella aerogenes and Enterobacter cloacae complex were the dominant species, followed by Klebsiella pneumoniae and Escherichia coli. The rate of carbapenemase gene positivity was 26.5% (196/740), and 93.4% (183/196) of these isolates were of the IMP type. Meanwhile, 315 isolates were subjected to antimicrobial susceptibility testing. Among them, 169 (53.7%) fulfilled only the IPM criteria (IPM criteria-only group) which were susceptible to meropenem, while 146 (46.3%) fulfilled the MEPM criteria (MEPM criteria group). The IPM criteria-only group and MEPM criteria group significantly differed in terms of carbapenemase gene positivity (0% vs. 67.8%), multidrug resistance rates (1.2% vs. 65.8%), and mortality rates (1.8% vs 6.9%).
CONCLUSION
CONCLUSIONS
The identification of CRE cases based solely on imipenem resistance has had a limited impact on clinical management. Emphasizing resistance to meropenem is crucial in defining CRE, which pose both clinical and public health burden. This emphasis will enable the efficient allocation of limited health and public health resources and preservation of newly developed antimicrobials.
Identifiants
pubmed: 38360618
doi: 10.1186/s12879-024-09107-4
pii: 10.1186/s12879-024-09107-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
209Investigateurs
Mari Matsui
(M)
Satowa Suzuki
(S)
Yohei Takahashi
(Y)
Nozomi Kamitaka
(N)
Shiho Takahashi
(S)
Nami Kanno
(N)
Takuya Ishi
(T)
Ryo Shimada
(R)
Hiroko Takahashi
(H)
Mayumi Ogawa
(M)
Koji Kikuchi
(K)
Hiroyuki Ueno
(H)
Kentaro Tomari
(K)
Junko Yoshihara
(J)
Naoshi Ando
(N)
Takako Katakura
(T)
Yuko Matsumoto
(Y)
Yoko Anzawa
(Y)
Satoko Haruna
(S)
Mikako Hosoya
(M)
Masanori Watahiki
(M)
Mika Shiroza
(M)
Koji Yokoyama
(K)
Makiko Noda
(M)
Ayako Furuta
(A)
Ryuji Kawahara
(R)
Kaoru Umeda
(K)
Takahiro Yamaguchi
(T)
Noriko Nakanishi
(N)
Kumiko Kuroda
(K)
Etsuko Saito
(E)
Yumiko Inoue
(Y)
Yuta Kawakami
(Y)
Tatsuaki Aota
(T)
Kanako Masuda
(K)
Hitoshi Ohtsuka
(H)
Chiemi Fukuda
(C)
Kazumi Seki
(K)
Yoko Iwashita
(Y)
Yukiko Asano
(Y)
Yuka Fukuguchi
(Y)
Emi Arikawa
(E)
Rika Maeda
(R)
Tsuyoshi Kudeken
(T)
Informations de copyright
© 2024. The Author(s).
Références
Logan LK, Weinstein RA. The epidemiology of Carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis. 2017;215:S28–36.
doi: 10.1093/infdis/jiw282
pubmed: 28375512
pmcid: 5853342
Tacconelli E, Sifakis F, Harbarth S, Schrijver R, van Mourik M, Voss A, et al. Surveillance for control of antimicrobial resistance. Lancet Infect Dis. 2018;18(3):e99–106.
doi: 10.1016/S1473-3099(17)30485-1
pubmed: 29102325
Altorf-Van Der Kuil W, Schoffelen AF, de Greeff SC, Ft Thijsen S, Alblas J, Notermans DW, et al. National laboratory-based surveillance system for antimicrobial resistance: a successful tool to support the control of antimicrobial resistance in the Netherlands. Euro Surveill. 2017;22(46):17–00062.
doi: 10.2807/1560-7917.ES.2017.22.46.17-00062
pubmed: 29162208
pmcid: 5718398
Zhang Y, Wang Q, Yin Y, Chen H, Jin L, Gu B, et al. Epidemiology of Carbapenem-resistant Enterobacteriaceae infections: report from the China CRE network. Antimicrob Agents Chemother. 2018;62(2):e01882–17.
doi: 10.1128/AAC.01882-17
pubmed: 29203488
pmcid: 5786810
Yamagishi T, Matsui M, Sekizuka T, Ito H, Fukusumi M, Uehira T, et al. A prolonged multispecies outbreak of IMP-6 carbapenemase-producing Enterobacterales due to horizontal transmission of the IncN plasmid. Sci Rep. 2020;10(1)
Suzuki S. A view on 20 years of antimicrobial resistance in Japan by two national surveillance systems: the National Epidemiological Surveillance of infectious diseases and Japan nosocomial infections Surveillance. Antibiotics. 2021;10(10):1189.
doi: 10.3390/antibiotics10101189
pubmed: 34680770
pmcid: 8532729
European Society of Clinical Microbiology and Infectious Diseases. The EUCAST guideline on detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. Version 2.0 [Internet]. 2017 [cited 2023 Jun 12]. Available from: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/EUCAST_detection_of_resistance_mechanisms_170711.pdf
Giske GC, Martinez-Martinez L, Cantón R, Stefani S, Skov R, Glupczynski Y, et al. EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. 2012.
Japan Nosocomial Infections Surveillance, Clinical Laboratory Division, Annual Open Report 2019 (All Facilities). [cited 2022 Feb 23]; Available from: https://janis.mhlw.go.jp/english/report/open_report/2019/3/1/ken_Open_Report_Eng_201900_clsi2012.pdf
Nakane K, Kawamura K, Goto K, Arakawa Y. Long-term colonisation by bla
doi: 10.1128/AEM.02929-15
pubmed: 26746714
pmcid: 4784029
CDC. Facility Guidance for Control of Carbapenem-resistant Enterobacteriaceae (CRE) Update-CRE Toolkit. 2015.
European Centre for Disease Prevention and Control. Annual surveillance reports on antimicrobial resistance [Internet]. [cited 2023 Jun 12]. Available from: https://www.ecdc.europa.eu/en/antimicrobial-resistance/surveillance-and-disease-data/report
Clinical and Laboratory Standards Institute. CLSI M100-S26. Performance Standards for Antimicrobial Susceptibility Testing, 26th Edition.
van Duin D, Arias CA, Komarow L, Chen L, Hanson BM, Weston G, et al. Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study. Lancet Infect Dis. 2020;20(6):731–41.
doi: 10.1016/S1473-3099(19)30755-8
pubmed: 32151332
pmcid: 7473597
Stewardson AJ, Marimuthu K, Sengupta S, Allignol A, El-Bouseary M, Carvalho MJ, et al. Effect of carbapenem resistance on outcomes of bloodstream infection caused by Enterobacteriaceae in low-income and middle-income countries (PANORAMA): a multinational prospective cohort study. Lancet Infect Dis. 2019;19(6):601–10.
doi: 10.1016/S1473-3099(18)30792-8
pubmed: 31047852
Hayakawa K, Nakano R, Hase R, Shimatani M, Kato H, Hasumi J, et al. Comparison between IMP carbapenemase-producing Enterobacteriaceae and non-carbapenemase-producing Enterobacteriaceae: a multicentre prospective study of the clinical and molecular epidemiology of carbapenem-resistant Enterobacteriaceae. J Antimicrob Chemother. 2020;75(3):697–708.
doi: 10.1093/jac/dkz501
pubmed: 31789374
Oka K, Matsumoto A, Tetsuka N, Morioka H, Iguchi M, Ishiguro N, et al. Clinical characteristics and treatment outcomes of carbapenem-resistant Enterobacterales infections in Japan. J Glob Antimicrob Resist. 2022;29:247–52.
doi: 10.1016/j.jgar.2022.04.004
pubmed: 35429667
Tamma PD, Goodman KE, Harris AD, Tekle T, Roberts A, Taiwo A, et al. Comparing the outcomes of patients with Carbapenemase-producing and non-Carbapenemase-producing carbapenem-resistant Enterobacteriaceae bacteremia. Clin Infect Dis. 2017;64(3):257–64.
doi: 10.1093/cid/ciw741
pubmed: 28013264
Villegas MV, Pallares CJ, Escandón-Vargas K, Hernández-Gómez C, Correa A, Álvarez C, et al. Characterisation and clinical impact of bloodstream infection caused by Carbapenemase-producing Enterobacteriaceae in seven Latin American countries. PLoS One. 2016;11(4):e0154092.
doi: 10.1371/journal.pone.0154092
pubmed: 27104910
pmcid: 4841576
Seo H, Lee SC, Chung H, Ra SH, Sung H, Kim MN, et al. Clinical and microbiological analysis of risk factors for mortality in patients with Carbapenem-resistant Enterobacteriaceae bacteremia. Int J Antimicrob Agents. 2020;56(4):106126.
doi: 10.1016/j.ijantimicag.2020.106126
pubmed: 32755654
Mariappan S, Sekar U, Kamalanathan A. Carbapenemase-producing Enterobacteriaceae: risk factors for infection and impact of resistance on outcomes. Int J Appl Basic Med Res. 2017;7(1):32–9.
doi: 10.4103/2229-516X.198520
pubmed: 28251105
pmcid: 5327604
Meini S, Tascini C, Cei M, Sozio E, Rossolini GM. AmpC β-lactamase-producing Enterobacterales: what a clinician should know. Infection. 2019;47(3):363–75.
doi: 10.1007/s15010-019-01291-9
pubmed: 30840201
Tamma PD, Doi Y, Bonomo RA, Johnson JK, Simner PJ. A primer on AmpC β-lactamases: necessary knowledge for an increasingly multidrug-resistant world. Clin Infect Dis. 2019;69(8):1446–55.
doi: 10.1093/cid/ciz173
pubmed: 30838380
pmcid: 6763639
Hao M, Ye M, Shen Z, Hu F, Yang Y, Wu S, et al. Porin deficiency in carbapenem-resistant Enterobacter aerogenes strains. Microb Drug Resist. 2018;24(9):1277–83.
doi: 10.1089/mdr.2017.0379
pubmed: 29653477
Chang YT, Siu LK, Wang JT, Wu TL, Chen YH, Chuang YC, et al. Resistance mechanisms and molecular epidemiology of carbapenem-nonsusceptible Escherichia coli in Taiwan, 2012–2015. Infect Drug Resist. 2019;12:2113–23.
doi: 10.2147/IDR.S208231
pubmed: 31406467
pmcid: 6642643
de Latour’s V, Laouénan C, Royer G, Carbonnelle E, Lepeule R, Esposito-Farèse M, et al. Mortality in Escherichia coli bloodstream infections: Antibiotic resistance still does not make it. J Antimicrob Chemother. 2020;75(8):2334–43.
doi: 10.1093/jac/dkaa161
Tsutsui A, Yahara K, Shibayama K. Trends and patterns of national antimicrobial consumption in Japan from 2004 to 2016. J Infect Chemother. 2018;24(6):414–21.
doi: 10.1016/j.jiac.2018.01.003
pubmed: 29428566
The summary of detection of overseas-type carbapenemase gene-positive strains in Carbapenem-resistant Enterobacteriaceae (CRE) surveillance, 2017-2018. Infectious agents Surveillance Report. 2019;40:158–9.